A. Klaumuenzer (Berlin, DE)
Klinik für Orthopädie und Unfallchirurgie Martin-Luther-Krankenhausbetrieb GmbHPresenter Of 1 Presentation
P257 - Matrix-assisted Autologous Cartilage Implantation in the Knee: A Systematic Analysis of Safety, Early Clinical and Radiological outcome.
Abstract
Purpose
The aim of this study was to evaluate the complication rate and early clinical and radiological outcome after matrix-assisted autologous chondrocyte implantation (m-ACI) in the knee.
Methods and Materials
A retrospective case series of patients aged 12-70 years with focal and full-thickness (ICRS 3 or 4) cartilage defects in the knee (max. 10 cm2) treated with matrix-assisted autologous cartilage implantation (BioSeed®-C, BioTissue SA, Switzerland). Complications requiring intervention were analysed on average 3±2 years after implantation. To assess the clinical outcome of implantation, a subset of patients who had KOOS scores before and 18 months after implantation was studied. The newly formed tissue structures were also assessed by MRI and rated using the MOCART score.
Results
138 patients (83 male, 55 female) with a mean age of 37 years and a mean defect size of 3.6 cm2 were included in the safety assessment. A total of 34 adverse events were observed (24.6%), the most common of them were hemarthrosis (8%), meniscus lesion (7%), and arthrofibrosis (7%). Only four incidents were classified as product-related, which consisted of incomplete defect filling (two patients; 1.4%), chondral delamination (one patient; 0.7%), inhomogeneity (one patient; 0.7%) or hypertrophy in the regenerated cartilage (one patient; 0.7%). The re-operation rate was 16.7% (23 incidents). Treatment failure due to joint infections was recorded in only two patients (1.4%). A sub-group of 19 patients (10 male, 9 female) with a mean age of 35 years and a mean defect size of 3.8 cm2 was included for the efficacy assessment. The KOOS score significantly increased in all subcategories after 18 months of implantation. Complete defect filling and integration into the adjacent cartilage were observed in 82% of the patients.
Conclusion
The results confirm that the implantation of the matrix-assisted autologous cartilage implant BioSeed®-C is a safe and effective approach for knee cartilage repair.
Presenter Of 1 Presentation
P257 - Matrix-assisted Autologous Cartilage Implantation in the Knee: A Systematic Analysis of Safety, Early Clinical and Radiological outcome.
Abstract
Purpose
The aim of this study was to evaluate the complication rate and early clinical and radiological outcome after matrix-assisted autologous chondrocyte implantation (m-ACI) in the knee.
Methods and Materials
A retrospective case series of patients aged 12-70 years with focal and full-thickness (ICRS 3 or 4) cartilage defects in the knee (max. 10 cm2) treated with matrix-assisted autologous cartilage implantation (BioSeed®-C, BioTissue SA, Switzerland). Complications requiring intervention were analysed on average 3±2 years after implantation. To assess the clinical outcome of implantation, a subset of patients who had KOOS scores before and 18 months after implantation was studied. The newly formed tissue structures were also assessed by MRI and rated using the MOCART score.
Results
138 patients (83 male, 55 female) with a mean age of 37 years and a mean defect size of 3.6 cm2 were included in the safety assessment. A total of 34 adverse events were observed (24.6%), the most common of them were hemarthrosis (8%), meniscus lesion (7%), and arthrofibrosis (7%). Only four incidents were classified as product-related, which consisted of incomplete defect filling (two patients; 1.4%), chondral delamination (one patient; 0.7%), inhomogeneity (one patient; 0.7%) or hypertrophy in the regenerated cartilage (one patient; 0.7%). The re-operation rate was 16.7% (23 incidents). Treatment failure due to joint infections was recorded in only two patients (1.4%). A sub-group of 19 patients (10 male, 9 female) with a mean age of 35 years and a mean defect size of 3.8 cm2 was included for the efficacy assessment. The KOOS score significantly increased in all subcategories after 18 months of implantation. Complete defect filling and integration into the adjacent cartilage were observed in 82% of the patients.
Conclusion
The results confirm that the implantation of the matrix-assisted autologous cartilage implant BioSeed®-C is a safe and effective approach for knee cartilage repair.